Alterations In NKG2A and NKG2C Subsets Of Natural Killer Cells following Epstein Barr Virus Reactivation In CTLA4Ig Based Haploidentical Transplantation Is Associated With Increased Chronic Graft-Versus-Host Disease.
The impact of newer approaches to haploidentical transplantation on Epstein Barr virus (EBV) is largely unknown. We prospectively evaluated the incidence of EBV reactivation and its impact on transplantation outcomes in 71 patients undergoing haploidentical transplantation with post-transplantation cyclophosphamide (PTCy) in combination with CTLA4Ig based T-costimulation blockade (COSBL). Eight patients developed EBV reactivation at a median of 96 days with no incidence of lymphoproliferative disorder (LPD). There was no impact of EBV reactivation on acute GVHD, non-relapse mortality, progression-free or overall survival. Despite an overall incidence of 19%, there was a significant increase in chronic GVHD following EBV reactivation (62.5% vs 8%, p=0.01). NKG2A subset of CD56 NK cells increased substantially and persisted following EBV reactivation and chronic GVHD, with a reciprocal decrease in NKG2C subset, whereas the reverse was witnessed in those without chronic GVHD (p< 0.01). Increase in NKG2C subset and a decrease in the NKG2A subset was witnessed within 3 months of subsidence of chronic GVHD. Thus, CTLA4Ig based haploidentical transplantation was associated with a low incidence of EBV reactivation without EBV-LPD. However, EBV reactivation was associated with a sustained alteration in NKG2A and NKG2C subsets of CD56 NK cells which might have a pathogenic role in chronic GVHD.